Disclaimer

You are now leaving www.esmya.com. Links to other websites are provided as a resource to our visitors.

Gedeon Richter accepts no responsibility for the content of other websites.

Esmya® Mode of Action

Esmya® directly acts on the endometrium, the fibroids and the pituitary gland

Esmya® Mode of Action

Esmya® is an oral Selective Progesterone Receptor Modulator (SPRM) characterized by a tissue‑specific partial progesterone antagonist effect1.

Esmya® directly acts on the endometrium, the fibroids and the pituitary gland1.

Endometrium Histological changes lead to reduced uterine bleeding
Fibroids Blockade of progesterone receptors, inhibition of cell proliferation and induction of
apoptosis reduces their size
Pituitary gland Ovulation is inhibited, LH and FSH secretion is partially suppressed, and mid-follicular
oestrogen levels are maintained

FSH, follicle-stimulating hormone; LH, luteinising hormone

Discover the mode of action of Esmya®

References

  • 125 Reference 1 - Esmya® SmPC. May 2015.
7fc16655c1
/wp-admin/options-general.php?page=emc2-popup-disclaimer%2Femc2pdc-admin.php
65dc6cecd1
2090
1
Accept
Decline
http://fibroidsconnect.com/
1

For Healthcare Professionals only

This information contained in this website was specifically created for healthcare professionals. Please tick here to confirm that you are a licensed healthcare professional.
Registration conditions of ESMYA® could differ in each country, please refer to your local regulations for more information.

Accept Decline